These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 36287217)

  • 41. Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study.
    Sato M; Inaba M; Yamada S; Emoto M; Ohno Y; Tsujimoto Y
    J Bone Miner Metab; 2021 Nov; 39(6):1082-1090. PubMed ID: 34324082
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study.
    Sølling AS; Harsløf T; Langdahl B
    J Bone Miner Res; 2021 Jul; 36(7):1245-1254. PubMed ID: 33813753
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Denosumab increases sublesional bone mass in osteoporotic individuals with recent spinal cord injury.
    Gifre L; Vidal J; Carrasco JL; Muxi A; Portell E; Monegal A; Guañabens N; Peris P
    Osteoporos Int; 2016 Jan; 27(1):405-10. PubMed ID: 26423406
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
    Saag KG; Pannacciulli N; Geusens P; Adachi JD; Messina OD; Morales-Torres J; Emkey R; Butler PW; Yin X; Lems WF
    Arthritis Rheumatol; 2019 Jul; 71(7):1174-1184. PubMed ID: 30816640
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
    Nakamura Y; Suzuki T; Kato H
    Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
    Bone HG; Wagman RB; Brandi ML; Brown JP; Chapurlat R; Cummings SR; Czerwiński E; Fahrleitner-Pammer A; Kendler DL; Lippuner K; Reginster JY; Roux C; Malouf J; Bradley MN; Daizadeh NS; Wang A; Dakin P; Pannacciulli N; Dempster DW; Papapoulos S
    Lancet Diabetes Endocrinol; 2017 Jul; 5(7):513-523. PubMed ID: 28546097
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case-control study.
    Ebina K; Nagayama Y; Kashii M; Tsuboi H; Okamura G; Miyama A; Etani Y; Noguchi T; Hirao M; Miura T; Fukuda Y; Kurihara T; Nakata K; Okada S
    Osteoporos Int; 2024 May; 35(5):841-849. PubMed ID: 38296866
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.
    Makras P; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Anastasilakis AD
    Bone; 2020 Sep; 138():115478. PubMed ID: 32534221
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer.
    Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
    J Bone Miner Metab; 2019 Mar; 37(2):301-306. PubMed ID: 29520506
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
    Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
    J Bone Miner Metab; 2019 Sep; 37(5):864-870. PubMed ID: 30868270
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of denosumab treatment in chronic liver disease patients with osteoporosis.
    Saeki C; Saito M; Oikawa T; Nakano M; Torisu Y; Saruta M; Tsubota A
    World J Gastroenterol; 2020 Sep; 26(33):4960-4971. PubMed ID: 32952342
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial.
    Iseri K; Iyoda M; Watanabe M; Matsumoto K; Sanada D; Inoue T; Tachibana S; Shibata T
    PLoS One; 2018; 13(3):e0193846. PubMed ID: 29543887
    [TBL] [Abstract][Full Text] [Related]  

  • 54. RE: One-Year Romosozumab Treatment Followed by One-Year Denosumab Treatment for Osteoporosis in Patients on Hemodialysis: An Observational Study.
    Pazianas M
    Calcif Tissue Int; 2023 May; 112(5):628-629. PubMed ID: 36574024
    [No Abstract]   [Full Text] [Related]  

  • 55. Bone Mass Gains After One Denosumab Injection Followed by Zoledronate.
    Everts-Graber J; Lehmann T
    J Clin Densitom; 2022; 25(3):293-298. PubMed ID: 35450795
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Four-Year Teriparatide Followed by Denosumab
    Hirooka Y; Nozaki Y; Okuda S; Sugiyama M; Kinoshita K; Funauchi M; Matsumura I
    Front Endocrinol (Lausanne); 2021; 12():753185. PubMed ID: 34646240
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Importance of Time Point-Specific Indirect Treatment Comparisons of Osteoporosis Treatments: A Systematic Literature Review and Network Meta-Analyses.
    Willems D; Javaid MK; Pinedo-Villanueva R; Libanati C; Yehoshua A; Charokopou M
    Clin Ther; 2022 Jan; 44(1):81-97. PubMed ID: 35058055
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nonresponder Considerations for Romosozumab Treatment.
    Tominaga A; Wada K; Okazaki K; Nishi H; Terayama Y; Shimamoto S; Kodama Y; Kato Y
    Calcif Tissue Int; 2023 Aug; 113(2):157-165. PubMed ID: 37138124
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Romosozumab is associated with greater trabecular bone score improvement compared to denosumab in postmenopausal osteoporosis.
    Hong N; Shin S; Lee S; Rhee Y
    Osteoporos Int; 2023 Dec; 34(12):2059-2067. PubMed ID: 37596432
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of denosumab on rheumatic diseases and refractory glucocorticoid-induced osteoporosis: a prospective study.
    Ishida T; Yoshida S; Fujiki Y; Hata K; Kotani T; Takeuchi T
    Arch Osteoporos; 2021 Feb; 16(1):39. PubMed ID: 33624165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.